key: cord-0848919-oaido57s authors: Wen, Hai-Jun; Liu, Feng-Liang; Huang, Ming-Xing; Luo, Rong-Hua; He, Wen-Bin; Feng, Jing; Chen, Fang-Liang; Cai, Qi-Chun; Ma, Hua-Juan; Yang, Zi-Feng; Zhou, Xi; Shang, You; Lyu, Xue-Mei; Zhang, Ding-Yu; Xiao, Fei; Shan, Hong; He, Jian-Xing; Zheng, Yong-Tang; Wu, Chung-I title: A proposal for clinical trials of COVID-19 treatment using homo-harringtonine date: 2020-10-12 journal: Natl Sci Rev DOI: 10.1093/nsr/nwaa257 sha: eb2662e9eee2e46c0914ab455ed8f4d5b89a3d0a doc_id: 848919 cord_uid: oaido57s nan 1) In vitro efficacy The original proposal cited the efficacy of HHT on coronaviruses in general. We now provide new data on SARS-CoV-2. The IC 50 is between <100 -350 nM depending on the conditions of the experiments and the lot of HHT used ( Figure 1A-1C) . It is also clear that, at 1 μM, the killing of the viruses is complete. As a comparison, remdesivir needs > 20 μM to achieve similar effect ( Figure 1D ). Hence, the efficacy of HHT in clearing SARS2-CoV-2 is in line with its efficacy against other coronaviruses (Andersen, et al. 2019; Cao, et al. 2015; Dong, et al. 2018; Kaur, et al. 2013) . In a recent study, Choy et al. (2020) tested 16 compounds for SARS-CoV-2 inhibition and HHT stands out as well. (We notice that the concentration needed to achieve EC 50 is often much higher in Choy et al.'s data than in other experiments by 10 -30 fold, although the relative efficacy among drugs is consistent with others.) As the half-cytotoxic concentration (CC 50 ) of HHT in mammalian cells usually exceeds 10uM (Andersen, et al. 2019; Cao, et al. 2015; Kaur, et al. 2013 ), HHT has a selectivity index (SI= CC 50 / IC 50 ) > 30. Taken together, these results confirm the promises of HHT in treating COVID-19. In a preliminary experiment, we infected ACE2 humanized mice with SARS-CoV-2. This inbred mice model was generated by integrating CRISPR-Cas9 and tetraploid complementation. The infected mice were either untreated as the control or treated by intraperitoneal injection of 40μg HHT in 100μl normal saline. The first dose is administered 2 hours before the virus challenge. Since HHT inhibits viral replication but does not block virus entry, the lead time of 2 hours should be sufficient for drug diffusion into the cells. HHT is administered daily for 3 days. On the third day post infection (d.p.i), mice were sacrificed and SARS-CoV-2 genomic RNA in lung tissues was measured by qRT-PCR. Among the 3 untreated mice, we obtained from 15 samples (five lobes of the lung from each mouse) the viral load of each sample, classified as ND (non-detectable), background (<10^2 copies/μg total RNA) or high load (10^5 -10^8). We should note that the infected mice, if untreated, would start to clear the viral load starting on the fourth day. The distribution of viral load, summarized as [ND, Low, High], was [3, 6, 6] for the control. In contrast, the distribution for the 3 HHTtreated mice was [9, 6, 0] . Although the sample size was small, HHT did repress the viral load to the background level in all 15 samples whereas the load was high in 6 of the 15 untreated samples. Given all the evidence, we believe that clinical trials should be the next step as suggested below. Proposed clinical trial -I. The pre-treatment From the standpoint of public health, the goal is to stop the spread of the virus and the progression of the infection, before the infection is confirmed. Here, we propose a two-step scheme aiming at the clearance of the viral load in the early phases of COVID infection. Late phases of infection with severe organ damages are not the target stages. For individuals who are not yet confirmed for infection but have reasons to suspect the possibility (such as close contacts with positive cases), we now recommend a pre-treatment procedure as follows. First, as shown by Wolfer et al. (Wölfel, et al. 2020 ) and He et al. , SARS-CoV-2 viruses may spend the first four days, on average, in the throat and nasal passage before they enter the lower respiratory tract. Second, the WHO guideline (Kratzel, et al. 2020 ) has shown that SARS-CoV-2 virus cannot survive for more than 30 seconds in 30% alcohol. Since many hard liquor and spirits have an alcohol content of above 30%, gargling 2-3 times a day with such hard liquor, each time for 30 seconds, might be effective in substantially arresting disease progression as well as inhibiting the spread of the viruses to others. This pre-treatment procedure is not likely to impair health (even if gargling is followed by swallowing, which should be discouraged). Furthermore, there have been various non-scientific indications of alcohol's efficacy in reducing the viral load during COVID-19 (Sattar, et al. 2020 ). Therefore, a large-scale clinical trial should be possible with little social and medical costs. If the disease symptoms do progress, then the HHT treatment would be an option. If the pre-treatment fails to clear the virus, an option would be the standard delivery of HHT by intravenous injection, which lasts at least 3 hours each day in a course of 4-6 days in treating Leukemia over several courses. 1) Intravenous injection -The safety level of HHT by intravenous injection is well known. i) In vitro dosage -Human HEK-293T cells can survive the 20 μM treatment for > 3 hours or 5 μM for > 24 hours. Indeed, 5 μM is far higher than necessary for suppressing SARS-CoV-2. ii) Dosage for the HHT treatment of leukemia -1.5 mg/m^2 (about 2.5 mg/[60kg person] or 100nM for adult patients) with daily continuous intravenous infusion for 3-6 hours up to 28 days. iii) It has been reported that the maximum tolerated and therapeutically effective dose of HHT for treating adult leukemia patients is 4mg daily for 14 days (Kantarjian, et al. 2001) . The treatment duration for COVID-19 is likely to be much shorter. 2) Nebulization -An alternative delivery would be by nebulization although the safety on humans has to be evaluated. There are reasons for preferring nebulization to intravenous injection in reducing the viral load and stopping the progression of symptoms. With nebulization, the drug concentration should be higher in the lungs than in other tissues, but probably for no more than a few hours after nebulization (Lemarie, et al. 2011) . The drug would then be distributed through blood circulation as in IV. In previous reports, HHT delivered by subcutaneous injection can only achieve a systemic concentration of 50 -60 nM while intravenous injection may achieve a higher concentration of 100-200 nM (Chan, et al. 1989; Nemunaitis, et al. 2013) . The HHT concentration achievable by intravenous injection is very close to the in vitro IC 50 at 100-300 nM, thus leaving almost no margin for errors. Furthermore, nebulization can be more easily administered by the patients themselves than IV when multiple applications per day are called for. A caveat is that aerosols generated during nebulization should be strictly regulated to avoid viral spread. Since the toxicity by nebulization, especially to the lungs, is not known, we have assessed the effect of HHT nebulization on two dogs, each weighing ~6kg. Dogs may be the only animal model on which nebulization can be applied. The dosage was ramped up from 0. 2 mg to 0.4, 0.6, 0.8, and 1mg per day. Each dosage was applied in two successive days with the whole treatment lasting 10 days. Each dog is monitored by daily physical assessment, complete blood count, chemistry profile, as well as a chest X-ray examination every two days. No toxicological changes related to the treatment was observed. Since the nebulization treatment in humans can be delivered evenly in the course of a day, 1 mg of HHT for humans should be well tolerated for several days. If the goal is to sustain the higher concentration of HHT in the lungs, we would recommend several episodes of nebulization per day (see also the next section). Based on the dosage in treating leukemia of a person of 60 kg, we suggest 1 mg per day in 15 ml saline by nebulization 5 times a day at the 4-hour interval, allowing 8 hours sleep. Each episode would be 15 minutes to nebulize 3 ml of solution. The total dose may be gradually ramped up to 4 mg per day if safety permits. The recommendation is based on our knowledge of sustaining the HHT concentration in the lungs. The optimal treatment cycles can only be found empirically. Nevertheless, given the in vitro and in vivo data, the scale of the clinical trial can be delineated. If the scheme works as expected, the nebulization of HHT should show a strong reduction in the viral load of several orders of magnitude within a few days. We estimate that a clinical trial of a modest number of patients (10 -50) should be sufficient to prove or dis-prove the efficacy of HHT. The main obstacle for the HHT clinical trials in many countries is the very low numbers of new COVID-19 patients. At the same time, medical facilities elsewhere may have an acute need for treating new COVID-19 patients by reducing their viral loads. For these facilities, the proposed scheme here may be an option for small-scale clinical trials. Kunming Police Dog Base of the Ministry of Public Security Joint Laboratory of Infectious Diseases and Health, Wuhan Institute of Virology & Wuhan Jinyintan Hospital, CAS, China 14. Department of Critical Care Medicine, Union Hospital, Tongji Medical College Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs Cephalotaxus Research Coordinating G 1976. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment Quantitation of homoharringtonine in plasma by highperformance liquid chromatography with amperometric detection Gene regulatory network stabilized by pervasive weak repressions: microRNA functions revealed by the May-Wigner theory The Natural Compound Homoharringtonine Presents Broad Antiviral Activity In Vitro and In Vivo Inhibition of translation in eukaryotic systems by harringtonine Temporal dynamics in viral shedding and transmissibility of COVID-19 Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised Homoharringtonine: history, current research, and future direction Inhibition of chikungunya virus replication by harringtonine, a novel antiviral that suppresses viral protein expression Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols Aerosolized Gemcitabine in Patients with Carcinoma of the Lung: Feasibility and Safety Study Detection for disease tipping points by landscape dynamic network biomarkers Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors Potential Role of Oral Rinses Targeting the Viral Lipid Envelope in SARS-CoV-2 Drug treatments for covid-19: living systematic review and network meta-analysis Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial Virological assessment of hospitalized patients with COVID-2019 Moral imperative for immediate release of 2019-nCoV sequence data Heightened protein-translation activities in mammalian cells and the disease/treatment implications Plasma Metabolomic and Lipidomic Alterations Associated with COVID-19 Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection We are grateful to Chen Hualan, Zhong Gongxun, Jiang Chengyu, Shi Suhua, Zhao Yong, He Xionglei, Cao Yongchang, and Zhang Yaping for helpful comments.